news
ProMIS Neurosciences Alzheimer's Drug Shows Early Safety, Biomarker Hits
ProMIS Neurosciences dropped early, positive blinded six-month safety and biomarker results for PMN310, their Alzheimer's drug in a Phase 1b trial. The study, involving mild cognitive impairment and mild AD patients, showed no severe amyloid-related imaging abnormalities in 136 people, suggesting a potentially safer path compared to other Alzheimer's treatments.
ProMIS Neurosciences dropped early, positive blinded six-month safety and biomarker results for PMN310, their Alzheimer's drug in a Phase 1b trial. The study, involving mild cognitive impairment and mild AD patients, showed no severe amyloid-related imaging abnormalities in 136 people, suggesting a potentially safer path compared to other Alzheimer's treatments.
The architecture take
So, a new Alzheimer's drug candidate, PMN310, is looking pretty good on the safety front in its early trials, with very low rates of brain swelling and microhemorrhages seen with other amyloid-targeting therapies. This matters because it hunts down toxic forms of amyloid beta, which might keep the brain a bit less inflamed than the total amyloid clearing approach of competitors like Leqembi. The market read here isn't just about Alzheimer's; it's about the entire approach to neurodegenerative diseases. We're moving from a sledgehammer to a scalpel for clearing out gunk in the brain. For you, it means less systemic noise, and hopefully, fewer of those nasty side effects. Watch if this selective targeting strategy becomes the new standard, pushing other, less selective drugs into a corner.